Cancer vaccine developers Madiha Derouazi and Elodie Belnoue laureates of the European Inventor Award 2022

New medical platform to make therapeutic cancer vaccines that help the immune system recognise and destroy cancer cells in the body of a patient

23-Jun-2022 - The European Patent Office (EPO) distinguished Swiss biotechnologist Madiha Derouazi and French immunologist Elodie Belnoue with the European Inventor Award 2022 in the "SME" category. The pair have developed a vaccine assembly platform called KISIMA to produce vaccines for treating different ...

Boehringer Ingelheim acquires swiss biotech start-up

17-Jul-2019 - Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first in class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently ...

AMAL Therapeutics closes series B financing round

Funds to be used for vaccine and technology platform development

06-Sep-2017 - AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the first tranche of its Series B financing round, raising €8 million (CHF 8.8 million). The Company will use the funds to progress its lead vaccine ...